Literature DB >> 26569195

Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.

Judith Namuyonga1, Sulaiman Lubega, Victor Musiime, Peter Lwabi, Irene Lubega.   

Abstract

BACKGROUND: Despite effective antiretroviral therapy (ART), HIV-infected children on treatment have been observed to have cardiac abnormalities. We sought to determine the prevalence, types and factors associated with cardiac abnormalities among HIV-infected Ugandan children on combination ART.
METHODS: We carried out a cross-sectional study from July 2012 to January 2013, at Joint Clinical Research Centre among HIV-infected children aged 1-18 years. Cardiac abnormalities were assessed using electrocardiography and echocardiography. CD4 counts, viral load and complete blood count were performed at enrollment. The prevalence of cardiac abnormalities was determined using simple proportions with the associated factors ascertained using logistic regression.
RESULTS: Among 285 children recruited, the median (interquartile range) age was 9 (6-13) years, 54% were female; 72% were on first line combination ART. Their mean (±SD) CD4 count was 1092 (±868.7) cells/mm; median (interquartile range) viral load was 20 (20-76) copies/mL. Ninety-four percent had adherence to ART of more than 95%. Cardiac abnormalities were detected in 39 (13.7%) children. The most common abnormalities by electrocardiography and echocardiography were nonspecific T wave changes (4.6%) and pericardial disease (thickened pericardium with or without pericardial effusion; 2.8%), respectively. No factor assessed was found to be significantly associated occurrence of cardiac dysfunction.
CONCLUSIONS: The prevalence of cardiac dysfunction among the HIV-infected children on ART was 13.7%, which was high, with nonspecific T wave changes and pericardial disease being the most frequent abnormalities observed. No factor assessed was found to be associated with cardiac dysfunction.

Entities:  

Mesh:

Year:  2016        PMID: 26569195      PMCID: PMC4752406          DOI: 10.1097/INF.0000000000000997

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  QTc interval prolongation in patients with HIV and AIDS.

Authors:  Mahmoud U Sani; Basil N Okeahialam
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

2.  Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren.

Authors:  Andrea Beaton; Emmy Okello; Peter Lwabi; Charles Mondo; Robert McCarter; Craig Sable
Journal:  Circulation       Date:  2012-05-24       Impact factor: 29.690

3.  Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.

Authors:  Roger J Pomerantz
Journal:  Clin Infect Dis       Date:  2001-11-21       Impact factor: 9.079

4.  Heart disease among children with HIV/AIDS attending the paediatric infectious disease clinic at Mulago Hospital.

Authors:  S Lubega; G W Zirembuzi; P Lwabi
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

5.  Cardiovascular manifestations of human immunodeficiency virus infection in infants and children.

Authors:  S E Lipshultz; S Chanock; S P Sanders; S D Colan; A Perez-Atayde; K McIntosh
Journal:  Am J Cardiol       Date:  1989-06-15       Impact factor: 2.778

6.  Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome.

Authors:  Inas Al-Attar; E John Orav; Vernat Exil; Sarah A Vlach; Steven E Lipshultz
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

7.  Cardiac morbidity and related mortality in children with HIV infection.

Authors:  L M Luginbuhl; E J Orav; K McIntosh; S E Lipshultz
Journal:  JAMA       Date:  1993-06-09       Impact factor: 56.272

8.  Pericardial effusion in AIDS. Incidence and survival.

Authors:  P A Heidenreich; M J Eisenberg; L L Kee; C A Somelofski; H Hollander; N B Schiller; M D Cheitlin
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

9.  Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen.

Authors:  Junko Tanuma; Azumi Ishizaki; Hiroyuki Gatanaga; Yoshimi Kikuchi; Satoshi Kimura; Michiaki Hiroe; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2003-09-05       Impact factor: 9.079

Review 10.  HIV infection, highly active antiretroviral therapy and the cardiovascular system.

Authors:  Giuseppe Barbaro
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

View more
  5 in total

Review 1.  Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.

Authors:  Sahera Dirajlal-Fargo; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-15       Impact factor: 5.495

Review 2.  HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

3.  Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART).

Authors:  Lisa J Frigati; Karryn Brown; Sana Mahtab; Leah Githinji; Diane Gray; Liesl Zühlke; Peter Nourse; Dan J Stein; Jaqueline Hoare; Mark F Cotton; Landon Myer; Heather J Zar
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

4.  Cardiopulmonary dysfunction in perinatally HIV-infected South African adolescents on antiretroviral therapy: baseline findings from the Cape Town Adolescent Antiretroviral Cohort.

Authors:  Leah N Githinji; Sana Mahtab; Liesl Zühlke; John Lawrenson; Landon Myer; Diane Gray; Heather Zar
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

5.  High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy.

Authors:  Edith D Majonga; Andrea M Rehman; Victoria Simms; Grace Mchugh; Hilda A Mujuru; Kusum Nathoo; Jon O Odland; Mohammad S Patel; Juan P Kaski; Rashida A Ferrand
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.